Could First-Mover Advantage Make Curetis Ripe For The Picking By Dx Players?
Executive Summary
German molecular diagnostics company Curetis may have missed its original forecast for a 2017 US launch of its flagship Unyvero infectious disease test platform, but CEO Oliver Schacht is confident that the all-clear from FDA is very close. When this crucial milestone is achieved, the firm will be the first in the US with a molecular diagnostic for lower respiratory tract infections. And the approval could increase Curetis' appeal as an acquisition target for larger diagnostics players.
You may also be interested in...
Device Debut: Curetis' Unyvero Infectious Disease Tester Earns De Novo Clearance
FDA granted de novo clearance to Curetis' Unyvero "sample-to-answer" diagnostic system and the Lower Respiratory Tract Infection Application Cartridge, the company announced April 3. Unyvero works with the Unyvero LRT Application Cartridge to provides rapid infectious disease testing directly from aspirate samples in less than five hours. The FDA decision comes a day after the Singapore Health Sciences Authority approved Curetis' Unyvero BCU Cartridge.
Curetis Appoints US Head
Molecular diagnostics specialist Curetis N.V. has appointed Christopher Bernard President and CEO of Curetis USA, Inc.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.